Metlife (MET) Buy, Sell or Hold

Metlife (MET)

85.58

-0.00 (0.00%)

as of Jun 18, 2026, 7:59:59 pm Market Open.

26 watching

DON'T BUY

Does not own shares. Financial services and insurance. Valuation is low and could be good time for investors. Does not own shares. Fundamentally a 6/10. Could be volatile. Better options out there for investors.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 27/22, Up 7.4%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with MET has triggered its stop at $65. To remain disciplined, we recommend covering the position at this time.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 27/22, Up 27.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MET has achieved its target at $77. To remain disciplined, we recommend covering half the position and trailing up the stop loss (from $62) to $67. If triggered, this would result in a net investment gain of 18%.

HOLD

Switch from Canadian insurers to MET? Hit a new high today. Likes it. Financials are at a historical discount. Likes banks, insurers and diversified financials. He wouldn't switch, as some Canadian valuations are quite cheap. Nice dividend of 2.6%.

HOLD

Model price of $87.26, 18% upside. Market really liked its write down on balance sheet or spinoff. Likes it here. Turned itself around. Will probably go to $80, and he'll evaluate it there.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 27/22, Up 22.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MET is progressing well. To remain disciplined, we now recommend trailing up the stop (from $52.50) to $62.00.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly This world leader in insurance and benefits is a TOP PICK. The company just announced a deal along with PRU to assume the $16 billion pension obligation of IBM -- right up its alley. We like the value here as the company is trading under book value, just beat analyst earnings expectations, and is projected to trade 7x earnings. It has managed to increase cash reserves, while aggressively retiring debt and buying back shares. Its dividend is backed by a payout ratio under 50% of cash flow. We recommend placing a stop loss at $52.50, looking to achieve $77 -- upside potential of 25%. Yield 3.2% (Analysts’ price target is $77.25)

BUY

The insurers have been in fire, like MetLife. He believes rates will go higher, so definitely stick with them.

DON'T BUY

It's fine, but he does not likes financials (or energy). He just likes MET's yield and that's it.

COMMENT

AIG-N vs. MET-N. AIG-N has been recapitalizing since the disaster of the financial crisis. MET-N did not suffer these issues. The life business is in pretty decent shape but he prefers Canadian lifecos. (Analysts’ price target is $55.57)

BUY

It’s pretty cheap, trading at 8.1 times. Their earnings in July were double year over year and beat expectations. They are growing globally and it’s a safe name with a low valuation. Couldn’t go wrong with this choice in the long term.

WAIT

MET vs. BAC. Dynamics of the two are different, so hard to compare. FMV potential of both is huge. But the market won't go, because interest rates are falling. Aren't any drivers to escalate earnings. Very cheap, but who knows when they're going to pop? (Analysts’ price target is $53.19)

DON'T BUY

The balance sheet is impaired and there should be write-offs, which he hasn't seen. He sees 32% upside with a $64 model price, but he'd be happy seeing this at $53.80. He would recommend this stock above this price. He has recommended MET before, but MET just can't get going. The balance sheet is ugly. Also, if interest rates fall to zero, all insurance companies will get hit.

PAST TOP PICK

(A Top Pick Mar 29/18, Up 3%) Slow or flar growth this and next year, but they are buying back stock. He sees 9% EPS growth this year. Their US retirement portfolio has been doing well. It's cheap at 8x PE and paying almost a 4% dividend. It's been stagnant for many years, but it has tailwinds of lower taxes and volume growth. They're growing in Asia and Europe.

DON'T BUY

Metlife vs. Prudential vs US banks Both are high quality and international. Strong. He doesn't love lifecos now, because there's a lot going on in health, such as the prevalance of diabetes. He wants to see higher interest rates which can benefit lifecos. As for banks, he'd stay away. The rates and yield curve have flattened. Met are doing the right thing, like a nice dividend and a big share buybacks. It isn't expensive and doing 10% earnings growth, but there are greener pastures elsewhere.

Showing 1 to 15 of 110 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Metlife (MET) Frequently Asked Questions

What is Metlife stock symbol?

Metlife is a American stock, trading under the symbol MET (previously MET-N on Stockchase) on the New York Stock Exchange (MET). It is usually referred to as NYSE:MET or MET

Is Metlife a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on MET (previously MET-N on Stockchase) on Stockchase. Read the latest expert commentary for Metlife.

Is Metlife a good investment or a top pick?

Metlife was recommended as a Top Pick by Cameron Hurst on 2019-03-06. Read the latest stock experts ratings for Metlife.

Why is Metlife stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Metlife.

Is Metlife worth watching?

Metlife is followed by 26 investors on Stockchase and is a trending stock that is worth watching.

What is Metlife stock price?

On 2026-06-18, Metlife (MET) stock closed at a price of $85.58.

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Metlife (MET)

Metlife(MET)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Metlife(MET)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Metlife(MET)

Metlife(MET)

Metlife(MET)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Metlife(MET)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Metlife(MET)

Metlife(MET)

Metlife(MET)

Metlife(MET)

Metlife(MET)

Metlife(MET)

Metlife(MET)

Metlife(MET)

Metlife(MET)